Comparison of weekly and 3-weekly schedule of docetaxel as second line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data from 818 patients

被引：0
|
作者：
Di Maio, M.
Perrone, F.
Chiodini, P.
Gallo, C.
Camps, C.
Quoix, E.
Schuette, W.
Gridelli, C.
机构：
[1] Ist Nazl Tumori, Unita Sperimentaz Clin, Naples, Italy
[2] Seconda Univ Napoli, Dipartimento Med Pubbl Clin & Prevent, Naples, Italy
[3] Hosp Gen Univ, Valencia, Spain
[4] Hop Lyautey, Strasbourg, France
[5] Martha Maria City Hosp Halle Doelau, Halle, Germany
[6] Azienda Osped S Giuseppe Moscati, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI25 / XI25
页数：1
相关论文
共 50 条
  • [41] Weekly docetaxel (TXT) and cisplatin (CIS) for chemonaive patients (Pts) with advanced non-small cell lung cancer (NSCLC)
    Aisner, J
    Geunsch, L
    Schwarz, S
    Zheng, L
    Wojtaszek, C
    Lutzker, S
    LUNG CANCER, 2005, 49 : S233 - S233
  • [42] Phase II trial of weekly docetaxel and carboplatin as first line chemotherapy in advanced or metastatic non small cell lung cancer (NSCLC).
    Chahine, GY
    Nasr, FL
    Kattan, JG
    Farhat, FS
    El Seoudi, ME
    Bachour, M
    Moukadem, WT
    Younes, FC
    Ghosn, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [43] Weekly paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC).
    Nakagawa, K
    Fukuoka, M
    Saijo, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 704S - 704S
  • [44] Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer
    Tibaldi, Carmelo
    Bernardini, Ilaria
    Chella, Antonio
    Russo, Francesa
    Vasile, Enrico
    Malventi, Michele
    Falcone, Alfredo
    CLINICAL LUNG CANCER, 2006, 7 (06) : 401 - 405
  • [45] Efficacy and toxicity of weekly paclitaxel as second/third line chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Caballero, C
    Camps, C
    Garde, J
    Juarez, A
    Blasco, A
    Berrocal, A
    Safont, M
    Bremnes, R
    Iranzo, V
    Sirera, R
    LUNG CANCER, 2005, 49 : S239 - S239
  • [46] Gefitinib versus docetaxel in patients with pretreated advanced non-small-cell lung cancer (NSCLC): meta-analysis from four randomized clinical trials
    Shepherd, Frances A.
    Douillard, Jean-Yves
    Fukuoka, Masahiro
    Saijo, Nagahiro
    Kim, Sang-We
    Cufer, Tanja
    Sellers, Mark, V
    Armour, Alison A.
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S291 - S291
  • [47] Weekly Paclitaxel as Third Line Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
    Belloni, P.
    Cozzi, C.
    Zannier, F.
    Corradini, G.
    Candido, P.
    Della Torre, S.
    Toniolo, D.
    Fariciotti, A.
    Vismara, A.
    Bollina, R.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S538 - S538
  • [48] Cost effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small-cell lung cancer (NSCLC) in Taiwan
    Hsia, T. C.
    Chang, G. C.
    Chen, Y. M.
    Lin, M. C.
    Su, W. C.
    Tsai, C. M.
    CM, Tsai
    Yang, L.
    Creeden, J.
    VALUE IN HEALTH, 2007, 10 (06) : A325 - A325
  • [49] A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
    Chen, Shuo
    Hu, Bin
    Li, Hui
    ONCOTARGETS AND THERAPY, 2018, 11 : 7691 - 7697
  • [50] Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis
    Yu, Guo-Can
    Yang, Jun
    Ye, Bo
    Xu, Li-Liang
    Li, Xiao-Yuan
    Zheng, Guan-Rong
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2019, 16 (06) : 7659 - 7670
12345